Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5514646 | LILLY | Insulin analogs modified at position 29 of the B chain |
May, 2013
(11 years ago) | |
US5461031 | LILLY | Monomeric insulin analog formulations |
Jun, 2014
(9 years ago) | |
US5474978 | LILLY | Insulin analog formulations |
Jun, 2014
(9 years ago) | |
US5747642 | LILLY | Monomeric insulin analog formulations |
Jun, 2014
(9 years ago) | |
US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(2 months from now) |
Humalog Mix 50/50 Kwikpen is owned by Lilly.
Humalog Mix 50/50 Kwikpen contains Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant.
Humalog Mix 50/50 Kwikpen has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Humalog Mix 50/50 Kwikpen are:
Humalog Mix 50/50 Kwikpen was authorised for market use on 22 December, 1999.
Humalog Mix 50/50 Kwikpen is available in injectable;injection dosage forms.
Humalog Mix 50/50 Kwikpen can be used as treatment of diabetes mellitus, use for the treatment of hyperglycemia.
The generics of Humalog Mix 50/50 Kwikpen are possible to be released after 09 August, 2024.
Market Authorisation Date: 22 December, 1999
Treatment: Use for the treatment of hyperglycemia; Treatment of diabetes mellitus
Dosage: INJECTABLE;INJECTION